Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Komarom – page 9

276 clinical trials in Komarom, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Komarom at a glance
276
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

276 trials in Komarom

Open in trial search

Partial seizures

Not yet recruiting

Long‑Term Safety and Effectiveness of 3-(7‑chloro‑1H‑indazol‑5‑yl)-2,5‑bis(trifluoromethyl)-3H‑imidazo[4,5‑b]pyridine in Adults with Refractory Focal Onset Epilepsy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Acute myeloid leukaemia

Not yet recruiting

A Study to Assess Effectiveness of IPN60340 with Drug Combination in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ipsen Pharma

Cardiac failure

Not yet recruiting

Efficacy and Safety of Fixed‑Dose Combination of Dapagliflozin, Bisoprolol Fumarate, and Eplerenone vs Usual Care in Hospitalized Acute Heart Failure Patients

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Type 2 diabetes mellitus+2

Not yet recruiting

A Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Prostate cancer

Not yet recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

Non-small cell lung cancer

Not yet recruiting

Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm malignant

Not yet recruiting

Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Sutro Biopharma Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Komarom

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on atherosclerotic cardiovascular disease prevention and innovative treatments for atrial fibrillation. Research aims to evaluate new therapeutic approaches for stroke prevention and cardiac event reduction.

  • Stroke Prevention Therapies
  • Cardiovascular Event Management
  • Blood Clot Prevention

Multiple trials comparing the effectiveness of novel medications against established treatments for heart conditions.

02 Metabolic Disorders

Clinical research examining treatments for Type 2 Diabetes Mellitus and mixed dyslipidemia. Studies evaluate new therapeutic agents aimed at improving metabolic health outcomes.

  • Diabetes Management
  • Lipid Disorders
  • Cardiovascular Risk Reduction

Innovative approaches being tested to address complex metabolic conditions and their complications.

03 Respiratory Medicine

Advanced research into treating Chronic Obstructive Pulmonary Disease, particularly focusing on patients with frequent exacerbations. Studies evaluate targeted biological therapies for respiratory conditions.

  • COPD Management
  • Exacerbation Prevention
  • Respiratory Function Improvement

Trials specifically designed to address severe respiratory conditions and improve patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.